Novozymes maintains 2018 outlook despite disappointing growth

Bioenergy advanced 9 percent in the Novozymes Q1 report, thus offsetting a sales setback in Agriculture and Feed.

Photo: Novozymes/ PR

Novozymes maintains its 2018 expectations for organic sales growth of 4-6 percent, announces the firm Wednesday morning CET in the Q1 interim report.

The EBIT margin is expected to be around 28 percent, while the bottom line is expected to land around the 2017 level of DKK 3,120 million (EUR 419 million).

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from EnergyWatch

New developer has 11GW offshore wind ready from inception

Profiles from European Energy, Ørsted and Centrica team up to found a new company aiming to develop solar, onshore wind, offshore wind and do power trading. Theres a hole in the market for us right now — in five years it will be closed, says director.

CIP hires Dutch profile

Current CFO at TenneT Otto Jager will join CIP as partner, with a primary focus on flagship funds.

Further reading

Related articles

Latest News

See all jobs